1. A multicenter prospective randomized controlled trial of cardiac resynchronization therapy guided by invasive dP/dt
- Author
-
Manav Sohal, MBBS, Shoaib Hamid, MD, Giovanni Perego, MD, Paolo Della Bella, MD, Shaumik Adhya, MD, John Paisey, MD, Tim Betts, MD, Ravi Kamdar, MD, Pier Lambiase, MD, Francisco Leyva, MD, Janet M. McComb, MD, Jonathan Behar, MD, Thomas Jackson, MD, Simon Claridge, MD, Vishal Mehta, MD, Mark Elliott, MD, Steven Niederer, PhD, Reza Razavi, MD, and C. Aldo Rinaldi, MD, FHRS
- Subjects
Acute hemodynamic response ,Cardiac resynchronization therapy ,Heart failure ,LV reverse remodeling ,Targeted lead placement ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: No periprocedural metric has demonstrated improved cardiac resynchronization therapy (CRT) outcomes in a multicenter setting. Objective: We sought to determine if left ventricular (LV) lead placement targeted to the coronary sinus (CS) branch generating the best acute hemodynamic response (AHR) results in improved outcomes at 6 months. Methods: In this multicenter randomized controlled trial, patients were randomized to guided CRT or conventional CRT. Patients in the guided arm had LV dP/dtmax measured during biventricular (BIV) pacing. Target CS branches were identified and the final LV lead position was the branch with the best AHR and acceptable threshold values. The primary endpoint was the proportion of patients with a reduction in LV end-systolic volume (LVESV) of ≥15% at 6 months. Results: A total of 281 patients were recruited across 12 centers. Mean age was 70.8 ± 10.9 years and 54% had ischemic etiology. Seventy-three percent of patients in the guided arm demonstrated a reduction in LVESV of ≥15% at 6 months vs 60% in the conventional arm (P = .02). Patients with AHR ≥ 10% were more likely to demonstrate a reduction of ESV ≥ 15% (84% of patients with an AHR ≥10% vs 28% with an AHR
- Published
- 2021
- Full Text
- View/download PDF